Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer

Biomarkers to identify metastatic breast cancer (mBC) patients resistant to CDK4/6 inhibition (CDK4/6i) are currently missing. We evaluated the usefulness of the monocyte-to-lymphocyte ratio (MLR), the neutrophil–to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) as predictive mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Moukas, Stefanos Ioannis, Kasimir-Bauer, Sabine, Tewes, Mitra, Kolberg, Hans-Christian, Hoffmann, Oliver, Kimmig, Rainer, Keup, Corinna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692150/
https://www.ncbi.nlm.nih.gov/pubmed/38040730
http://dx.doi.org/10.1038/s41598-023-47874-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692150/
https://www.ncbi.nlm.nih.gov/pubmed/38040730
http://dx.doi.org/10.1038/s41598-023-47874-3

Ejemplares similares